NLRP3 and hyperuricemia: In Figure 6C, high dose can significantly reduce the level of IL-1β in hyperuricemia mice (p < 0.001), and in Figure 6D, compared with the model group, the high dose group had a significant effect on reducing serum NLRP3 (p < 0.001).